Paul Tudor Jones Summit Therapeutics Inc. Transaction History
Tudor Investment Corp Et Al
- $29 Billion
- Q1 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 11,800 shares of SMMT stock, worth $338,188. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,800
Previous 11,200
5.36%
Holding current value
$338,188
Previous $199,000
14.07%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
246Shares Held
87.3MCall Options Held
1.77MPut Options Held
2.49M-
Baker Bros. Advisors LP New York, NY24.4MShares$700 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$334 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$226 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$188 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$139 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $5.77B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...